Kumovis
Kumovis develops and manufactures 3D printers optimized for processing high-performance polymers for medical applications. The company's flagship product, the Kumovis R1 printer, is designed to produce patient-specific implants and surgical instruments from materials like PEEK, PEKK, and other medical-grade polymers. The printer features a clean room environment, precise temperature management, and a closed-loop quality monitoring system to meet the stringent requirements of the medical industry.
- CEO / Founder
- Miriam Haerst, Stefan Leonhardt (Co-CEOs at time of acquisition)
- Team Size
- 11-50
- Stage
- Acquired
- Total Funding
- Acquired
- Latest Round
- Acquired
Technology & Products
Key Products
Kumovis R1 3D Printer (rebranded as EXT 220 MED by 3D Systems)
Technological Advantage
The company's technology enables decentralized manufacturing of medical devices, allowing hospitals and clinics to produce custom implants and instruments on-demand. This reduces lead times, lowers costs, and improves patient outcomes. The acquisition by 3D Systems provides Kumovis with access to a global distribution network and a broader portfolio of materials and technologies, further strengthening its market position.
Patent position
Kumovis filed 23 patent families across all years, compared with 494 for Stratasys and 185 for EOS. AMPulse analysis
- Filing momentum
- 3 families filed 2022–2024, 18 in 2019–2021
- Filed in
- EP 43%US 39%WO 22%CN 17%
- Named competitors, AM patent families
- Stratasys 494EOS 185
23 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.
Differentiation
Value Proposition
Kumovis provides a complete solution for medical 3D printing, enabling the production of high-quality, patient-specific medical products at the point of care. The company's technology allows for the use of high-performance polymers, which are ideal for demanding medical applications, and ensures a sterile and controlled manufacturing process.
How They Differentiate
As part of 3D Systems, Kumovis continues to differentiate through its specialized extrusion technology for medical-grade, high-performance polymers and integrated clean room solutions. Its unique capabilities enhance 3D Systems' comprehensive portfolio for patient-specific medical applications, offering a highly specialized and reliable 3D printing solution.
Market & Competition
Target Customers
Medical device manufacturers, hospitals, and research institutions.
Industry Verticals
Medical, Healthcare
Competitors
As a 3D Systems company, Kumovis's competitors are now aligned with 3D Systems' broader additive manufacturing competitors in the medical sector, such as Stratasys and EOS.
Growth & Milestones
Growth Metrics
Acquired by 3D Systems in 2022.
Major Milestones
2017: Company founded., 2018: Won the Munich Business Plan Competition., 2019: Launched the Kumovis R1 3D printer., 2020: Closed a €3.6 million Series A funding round., 2022: Acquired by 3D Systems.
Notable Customers
Information not publicly available.
AM patents
AM-relevant patents linked to this company.
- Patents
- 29
- Granted
- 4
- Families
- 23
Leading domains: process (29), equipment (16), application (13)
Filings by year: 2024: 1 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 12 · 2017: 4
- POSITIONING SYSTEM FOR AN ADDITIVE MANUFACTURING SYSTEM, AND ADDITIVE MANUFACTURING SYSTEM2021032410 · WO
- 3D-PRINTED SEMI-FINISHED PART FOR MEDICAL DEVICE MANUFACTURING AND MEDICAL DEVICES THEREOF20240122715 · US
- MANUFACTURING OBJECTS WITH SEAMLESS SOLID-TO-POROUS TRANSITIONS4744864 · EP
- BOTTOM ELEMENT FOR AN ADDITIVE MANUFACTURING SYSTEM, AND ADDITIVE MANUFACTURING SYSTEM112406104 · CN
- A METHOD OF PRODUCING A COMPONENT, AND THE COMPONENT ITSELF20250001693 · US
Funding rounds
- Acquisition$37.7M2022-04Lead: 3D Systems · Source